MEK1/2 as a Therapeutic Target in Sickle Cell Disease.

Loading...
Thumbnail Image

Date

2019-01

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

78
views
28
downloads

Citation Stats

Abstract

Identification of novel therapeutic targets has improved diagnostics and treatment of many diseases. Many innovative treatment strategies have been developed based on the newly identified biomarkers and key molecules. Most of the research focused on ways to manipulate signaling pathways by activating or suppressing them, validate new therapeutic targets for treatment, and epigenetic treatment of diseases. With the identification of aberrations in multiple growth pathways, the focus then shifted to the small molecules involved in these pathways for targeted therapy. In this communication/short review, we highlight the importance of identification of abnormal activation of the mitogen-activated protein kinase (MAPK), ERK1/2, and its upstream mediator MEK1/2, in erythrocytes in patients with sickle cell disease (SCD) critical for the adhesive interactions of these cells with the endothelium, and leukocytes promoting circulatory obstruction leading to tissue ischemia and infraction. We also discuss how targeting this signaling cascade with MEK1/2 inhibitors can reverse acute vasoocclusive crises in SCD.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.23937/2469-5696/1410038

Publication Info

Zennadi, Rahima (2019). MEK1/2 as a Therapeutic Target in Sickle Cell Disease. International journal of blood research and disorders, 6(1). 10.23937/2469-5696/1410038 Retrieved from https://hdl.handle.net/10161/19551.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.